SCHEMBL1635346

SCHEMBL1635346

Cc1c2nc3ccc(NC(=O)CCNC(=O)OC(C)(C)C)cc3oc-2c(C)c(=O)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HIF1A Q16665 1/20 0.41
POLB P06746 2/20 0.41
CA1 P00915 3/20 0.40
CA2 P00918 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
LDHA P00338 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SUV39H2 Q9H5I1 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ABL1 P00519 1/20 0.39
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1636865 0.86 KDM4E (0.41) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL5483503 0.86 ADORA3 (0.41) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL1635348 0.85 SUV39H2 (0.40) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL1719827 0.82 POLB (0.45) KDM4EALDH1A1GLAGAAMAPT
Trifluoroacetic Acid SCHEMBL1636097 0.78 SMN1; SMN2 (0.45) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL1635427 0.76 TLR7 (0.41) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL1635253 0.76 TLR7 (0.41) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL8692897 0.72 CA1 (0.66) KDM4EGAAPOLBCA1CA2
SCHEMBL14911359 0.71 SMN1; SMN2 (0.64) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL2244763 0.70 ALDH1A1 (0.59) KDM4EALDH1A1GLAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786828-B1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2012-01-11 EP disclosed
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed
EP-1786828-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX (FR) 2007-05-23 EP disclosed
WO-2006030119-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY bioMérieux (FR) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP KDM4E 2742/4885ALDH1A1 639/4885GLA 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.